-
ALSO READ
Five drug makers collaborate for clinical trial of Molnupiravir
Torrent Pharma gains after ICRA revises credit outlook to 'positive'
Barometers trade near day's high; breadth remains strong
Select pharma stocks, RIL, NBCC (India) in focus
CARE Ratings upgrades credit rating of bank facilities of IOL Chemicals
-
On a consolidated basis, Torrent Pharmaceuticals' net profit rose 1.93% to Rs 316 crore on a 5.94% increase in net revenue from operations to Rs 2,137 crore in Q2 FY22 over Q2 FY21, bouyed by strong momentum in branded generic markets.
On a consolidated basis, gross profit rose 5% to Rs 1,542 crore in Q2 September 2021 as compared to Rs 1,463 crore in Q2 September 2020. EBITDA jumped 11% to Rs 711 crore in Q2 FY22 as against Rs 641 crore in Q2 FY21. R&D spend gained 9% to Rs 130 crore in Q2 September 2021 from Rs 119 crore in Q2 September 2020.
India revenues stood at Rs 1,087 crore during the quarter, growing by 13% over the corresponding quarter, last year. Underlying growth adjusted for dispatch related delays last year was at 16%. As per secondary market data (AIOCD), Torrent Pharmaceuticals' Q2 FY22. IPM growth stood at 15%. MR productivity for the quarter was at Rs 9.90 lakh with MR strength of 3,600.
Shares of Torrent Pharmaceuticals slipped 1.82% to Rs 2,888.70 on BSE. Torrent Pharmaceuticals (TPL) is the eighth largest player in the domestic pharmaceutical market with a presence in therapeutic segments like CVS, GI, CNS and VMN. The company has an arrangement with Novo Nordisk for manufacturing and supplying insulin for the Indian market. The exports business of TPL is carried out both by its foreign subsidiaries as well as directly by the parent company. TPL markets both branded generics and generic generics, and participates in the institutional segment of export markets.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU